XORTX Therapeutics Inc Total Liabilities
XORTX Therapeutics Inc total liabilities. Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) has total liabilities worth CA$837.41K CAD (≈ $605.77K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See XRTX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of XORTX Therapeutics Inc (2018–2024)
Total liabilities of XORTX Therapeutics Inc from 2018 to 2024. This chart illustrates how XORTX Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
XORTX Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of XORTX Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ScandiDos AB
ST:SDOS
|
Sweden | Skr24.31 Million |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
USA | $507.96 Million |
|
Technoplus Ventures Ltd
TA:TNPV
|
Israel | ILA25.09 Million |
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
India | Rs381.79 Million |
|
NR 21 S.A.
PA:NR21
|
France | €30.30K |
|
Megapower Makmur TBK PT
JK:MPOW
|
Indonesia | Rp38.61 Billion |
|
Capricorn Energy PLC
LSE:CNE
|
UK | GBX139.75 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down XORTX Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of XORTX Therapeutics Inc.
Liquidity & Leverage Metrics
XORTX Therapeutics Inc Total Liabilities Ratios Explained
XORTX Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XORTX Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XORTX Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of XORTX Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$757.99K ≈ $548.32K |
-8.23% |
| 2023-12-31 | CA$825.94K ≈ $597.47K |
-84.62% |
| 2022-12-31 | CA$5.37 Million ≈ $3.88 Million |
+1.33% |
| 2021-12-31 | CA$5.30 Million ≈ $3.83 Million |
+412.31% |
| 2020-12-31 | CA$1.03 Million ≈ $748.13K |
-20.43% |
| 2019-12-31 | CA$1.30 Million ≈ $940.18K |
+37.72% |
| 2018-12-31 | CA$943.70K ≈ $682.66K |
-- |
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the … Read more